Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Guidant Mini III

This article was originally published in The Gray Sheet

Executive Summary

Guidant Mini III: Shipments of the 48 cc, 90 g single chamber pacer/implantable cardioverter defibrillator are anticipated to commence in March. Guidant received FDA approval via premarket approval application supplement on Jan. 23 and will ramp up manufacturing capability prior to shipping, the firm states. The device is a smaller version of the firm's 59 cc, 115 g Mini II, and incorporates Guidant's new Quick Check and Quick Notes features which "allow the clinician to easily and quickly perform a comprehensive series of automatic tests and follow-up device operations" to facilitate patient management, Guidant states. The device uses Guidant's Endotak lead and Triad three-electrode energy defibrillation system...

You may also be interested in...



US Wellness Market Deals: Unilever Tries On SmartyPants, Kind Cooks Up Nature’s Bakery Deal

Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.

Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal

Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.

Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel